Companies › PRG Science & Technology
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Progerinin | – | Phase 2 | Hutchinson-Gilford Progeria Syndrome; Werner Syndrome | Dec 2027 |
| Amisodin | – | Phase 1 | Amyotrophic Lateral Sclerosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06775041 | Progerinin | Phase 2 | Hutchinson-Gilford Progeria Syndrome | Metabolic and endocrine | Mar 2026 |
| NCT07221240 | Amisodin | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | May 2026 |
| NCT05847179 | Progerinin | Phase 2 | Werner Syndrome | Metabolic and endocrine | Dec 2027 |
No annotated target.
–
Urovant Sciences Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen Beijing Suncadia Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.